Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.

Saved in:
Bibliographic Details
Title: Overview of the regulatory approval of tecovirimat intravenous formulation for treatment of smallpox: potential impact on smallpox outbreak response capabilities, and future tecovirimat development potential.
Authors: Russo AT; SIGA Technologies, Inc, Corvallis, OR, USA., Grosenbach DW; SIGA Technologies, Inc, Corvallis, OR, USA., Honeychurch KM; SIGA Technologies, Inc, Corvallis, OR, USA., Long PG; SIGA Technologies, Inc, Corvallis, OR, USA., Hruby DE; SIGA Technologies, Inc, Corvallis, OR, USA.
Source: Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2023 Mar; Vol. 21 (3), pp. 235-242. Date of Electronic Publication: 2023 Feb 02.
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 101181284 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8336 (Electronic) Linking ISSN: 14787210 NLM ISO Abbreviation: Expert Rev Anti Infect Ther Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1744-8336
DOI:10.1080/14787210.2023.2170350